Business Wire

Transphorm Ships Over Half a Million GaN Power Devices for Multi-kilowatt Class Applications

7.11.2019 16:00:00 EET | Business Wire | Press release

Share

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V gallium nitride (GaN) semiconductors—disclosed that it has shipped more than 500 thousand high voltage GaN FETs. The company hit this milestone as customers continue to adopt its high quality-high reliability GaN platform.

High Voltage GaN Adoption

Customers in the broad industrial, infrastructure and IT, and PC Gaming markets have publicly announced in-production devices built with Transphorm’s GaN technology. They illustrate the rising confidence in GaN solutions that are projected to be an attractive market.

In fact, industry analyst firm IHS Markit Technology, now a part of Informa Tech, forecasts the total GaN power discrete, module, and system IC revenues to reach $1.2 billion by 2028. Approximately $750 million of those revenues (almost two-thirds of the total market) will be driven by high voltage GaN solutions.1

“We came to market with the most robust, two-chip normally-off device at a time when the industry was more familiar with single-chip normally-off Silicon MOSFETs,” said Primit Parikh, Co-founder and COO, Transphorm. “As proven by our public momentum and also that of other reputable manufacturers like Power Integrations in the consumer adapter space, the two-chip normally-off GaN solution is the most practical high voltage GaN FET design today. In fact, it’s this design that enables Transphorm’s GaN to deliver high performance with strong robustness, which has led to more than 5 billion hours (with <2 FIT) of field reliability data to date.”

Transphorm’s adoption success continues to be driven largely by the Quality and Reliability (Q+R) of its products. This Q+R is backed by the company’s robust normally-off GaN platform, strong control of its epitaxial process, and manufacturing capability—which is well-positioned to meet the volume and quality requirements of various cross-industry markets from consumer adapters to automotive. Together, these elements enable the company to produce GaN FETs that offer unparalleled reliability, designability, drivability, and reproducibility.

“Following our success in the core higher power markets targeted by GaN, we’re also working with customers in fast growing markets that are underserved by Silicon such as consumer adapters and set-top boxes,” said Philip Zuk, VP of Worldwide Technical Marketing and North American Sales, Transphorm. “Consider that the majority of products we’ve shipped to date were targeted for higher power applications. Those 500 thousand-plus 650V FETs equate to more than 4 million lower power (sub 100 Watts) FETs, demonstrating our volume production capabilities.”

Field Reliability

A year ago, Transphorm released the first complete set of validation data for high voltage GaN power semiconductors. Today, the company formally released its latest field reliability data. With more than five billion hours in the field, Transphorm’s GaN technology currently has a <2.0 FIT rate at <19.8 PPM per year. For more information on device Quality + Reliability, visit the company’s Q+R webpage.

Welcome to the GaN Revolution!

Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power conversion applications. Holding the largest IP portfolio (1000+ issued and pending patents worldwide), Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified GaN FETs. This is due to a vertically-integrated business approach, which allows for innovation at every development stage: design, fabrication, device, and application support. Website: www.transphormusa.com Twitter: @transphormusa

1 SiC & GaN Power Semiconductors Report, IHS Markit, May 2019

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Ailara
211 Communications
heather@211comms.com
P: +1.973.567.6040

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye